Engflag

Mesterolone

Quick links to important sections

Mesterolone

Mesterolone_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mesterolone

Property Description
Active Ingredient Mesterolone
Form Oral Tablet
Pharmacological Class Synthetic Androgen / AAS
Common Use Androgen Replacement Therapy
Origin Synthetic derivative of Dihydrotestosterone (DHT)

Mesterolone's Classification and Chemical Identity

Mesterolone is an oral synthetic androgen that is formally classified as an anabolic-androgenic steroid (AAS). This drug is a single-ingredient product designed to act as a potent androgen receptor agonist in the body, primarily mimicking the actions of the natural male hormone, dihydrotestosterone (DHT). The active ingredient, Mesterolone, is chemically known as 1alpha -methyl-5alpha -dihydrotestosterone, which underscores its synthetic, derived origin from the parent hormone. Mesterolone is an orally active steroid, a feature often noted in the context of its therapeutic application.

Key Features: Form, Origin, and Non-Aromatization

The standard pharmaceutical delivery form of Mesterolone is an oral tablet, making the medication convenient for oral administration. This specific synthetic compound is differentiated from many other androgens by its unique chemical property: it is non-aromatizable, meaning it cannot be converted into estrogen within the body. This characteristic, which is clinically recognized in endocrinology, is a key differentiating factor in its mechanism compared to traditional testosterone. This non-aromatizable nature establishes a distinct pharmacological profile.

General Therapeutic Purpose of the Synthetic Androgen

The general therapeutic role of Mesterolone is to address clinically recognized states of androgen deficiency in adult males. By providing a source of exogenous androgens, the compound supports the maintenance of male secondary sexual characteristics and key physiological processes that require adequate androgenic stimulation. Mesterolone's targeted action of substituting for or supplementing natural androgens defines its high-level use in androgen replacement therapy.

What side effects are possible with Mesterolone?

Possible Side Effects and Safety Information

The safety profile of Mesterolone, an oral synthetic androgen, is defined by its hormonal activity and documented risks as classified by regulatory authorities. Adverse reactions are grouped by System Organ Class (SOC), including effects on the Reproductive system and breast disorders and the Skin and subcutaneous tissue disorders.

Officially Documented Adverse Reactions

The frequency for many listed side effects, such as acne, alopecia (scalp hair loss), headache, and abdominal pain, is classified as Not Known in official labeling, meaning it cannot be estimated from available data. Androgenic effects, including an increased number of erections and priapism (a prolonged erection), have also been documented. If frequent or very prolonged erections occur, this is a time-related safety pattern that requires treatment suspension or dose reduction to avoid potential physical damage.

Serious Safety Considerations

Regulatory documentation highlights the potential for rare but serious adverse reactions impacting the Hepato-biliary system. These include reports of benign and malignant liver tumours (hepatic neoplasms). In isolated instances, these tumours have been associated with life-threatening intra-abdominal haemorrhage.

Population-Specific Safety and Restrictions

Treatment with Mesterolone is intended exclusively for male patients. Safety constraints require regular examinations of the prostate as a precautionary measure, especially in older male patients, due to the potential for stimulating pre-existing conditions like prostatic hyperplasia. The medicine is formally restricted from use in individuals with a history of prostatic carcinoma, male breast cancer, or known liver tumours.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Mesterolone overdose is structured around two distinct points: the acute toxicity classification and the mandated emergency response to certain severe symptoms observed during treatment.

Regulatory documentation consistently states that Mesterolone is classified as non-toxic following acute single administration, meaning that no ill-effects or systemic toxicity are expected or reported after an inadvertent ingestion of a multiple dose. Accordingly, the necessity for treatment following this type of acute overdosage is generally unnecessary. In rare instances where a large ingestion is discovered within a specific time frame of two to three hours, gastric lavage is an officially described and permissible supportive measure. No specific antidote for Mesterolone overdose is known or documented.

In a separate regulatory requirement, immediate medical attention or hospitalisation must be sought if certain severe symptoms are experienced while taking the medication. These symptoms include severe, prolonged stomach pain or tenderness, or signs of liver enlargement or intra-abdominal haemorrhage. Regulators specify that these severe manifestations require urgent medical assessment to rule out the possibility of a serious complication like a liver tumour.

Therapeutic Uses of Mesterolone

What Mesterolone Treats: Main Uses and Benefits

Mesterolone is commonly used to help with conditions characterized by symptomatic androgen deficiency and confirmed male hypogonadism. It may be part of symptomatic management for conditions presenting with systemic or localized discomfort, assisting with maintaining functional stability. The medication is considered relevant for easing symptom clusters that may become disruptive, particularly those related to sexual health, physical energy, and age-related hormonal decline.

The primary therapeutic applications are commonly used to help with conditions involving confirmed male hypogonadism, supporting specific instances of androgen-related male infertility (oligospermia), and addressing physical and neuro-psychological symptoms of the Aging Male Syndrome.

“Mesterolone is applied in contexts where additional symptomatic support is needed, contributing to improved comfort during symptomatic phases.”

Quick Fact: Relief for Vitality Deficits

Mesterolone contributes to improved comfort by addressing physical and sexual symptoms that interfere with daily functioning, such as reduced libido, difficulties with potency, and feelings of profound physical fatigue linked to low hormone levels. This supports the patient during difficult episodes by easing distress.

Regulatory References

  1. NPS MedicineWise (Australia)

Eligibility and Restrictions for Use

Who can and cannot use Mesterolone?

The population eligibility for Mesterolone is narrowly defined by regulatory authorities and is primarily restricted to adult male patients with diagnosed androgen deficiency. The official product information establishes multiple absolute contraindications and population-specific restrictions.

Category Regulatory Eligibility Status
Populations Allowed Adult Males only.
Populations Contraindicated Females (all ages, including pregnant/lactating). Males with carcinoma of the prostate or male breast carcinoma. Patients with a previous or existing liver tumor (benign or malignant). Prepubertal Boys (before the end of puberty). Patients with known hypersensitivity to the active substance.
Age-Related Restrictions Children/Adolescents: Not recommended; contraindicated in prepubertal boys. Older Males (Geriatric): Use requires special caution with mandated regular prostate examination.
Condition-Specific Rules Organ Insufficiency: Use requires caution in patients with severe cardiac, hepatic, or renal insufficiency due to the risk of fluid retention.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Mesterolone's interaction profile, as defined by official regulatory labeling, primarily involves pharmacodynamic effects on co-administered medications, necessitating close monitoring rather than mandatory contraindications. These interactions generally result in an amplification of the effects of other drugs or an additive risk for specific adverse events.

Documented Pharmacodynamic Interactions

Co-administered Medicine Class Resulting Interaction Constraint
Oral Anticoagulants (e.g., Warfarin) May increase the anticoagulant effect, requiring close monitoring of coagulation status.
Antidiabetic Agents (e.g., Insulin, Oral Hypoglycemics) May increase the blood-sugar-lowering effect, requiring careful glucose monitoring.
Corticosteroids and ACTH May increase the risk of fluid retention (edema), particularly in patients with pre-existing heart or kidney conditions.
Cyclosporine Associated with an increased risk of hepatotoxicity (liver damage).

Other Interaction Considerations

Certain medicines known as enzyme inducers, such as the anticonvulsants Phenobarbital and Phenytoin, may potentially reduce the therapeutic effect of Mesterolone. No specific timing separation requirements with food or other medications are explicitly documented in the official regulatory guidance for this product. All combinations listed above require vigilance and potential dose adjustments for the interacting medication.

Mechanism of Action

How Mesterolone Works

Mesterolone functions as a synthetic androgen receptor (AR) agonist. Its chemical structure confers resistance to metabolic conversion by the enzymes 5alpha-reductase and aromatase in target tissues. This property prevents its significant transformation into dihydrotestosterone (DHT) or estrogenic metabolites, which distinguishes its pharmacological activity from endogenous testosterone.

Binding to the AR forms a ligand-receptor complex which then translocates to the cell nucleus. Inside the nucleus, the complex interacts with Androgen Response Elements (AREs) on DNA. This interaction modulates the rate of gene transcription, altering the synthesis of specific proteins. This cascade affects cellular processes such as growth, differentiation, and metabolism in androgen-responsive cells.

Secondary to AR agonism, Mesterolone can also competitively bind to Sex Hormone-Binding Globulin (SHBG) in the circulation. This competitive binding alters the proportion of circulating unbound testosterone, thereby modulating the overall androgenic environment within the physiological system.

Dosage and Administration Information

Mesterolone is available as an oral tablet and must be used strictly according to instructions for administration and dosing regimen to ensure proper compliance and efficacy.

Administration and Dosage Structure

The medicine is prescribed to be administered in a structured, two-phase regimen: an initial higher dose (initial phase) followed by a reduced long-term dose (maintenance phase). The dosage is typically individualized based on the condition being addressed.

Administration Component General Guideline
Route of Administration Oral (tablet swallowed whole with liquid).
Timing in Relation to Meals Tablets are often directed to be taken with food or after a meal.
Initial Daily Dose Generally 75 mg to 100 mg per day.
Maintenance Daily Dose Generally 25 mg to 75 mg per day, seeking the minimum effective dose.

Frequency and Procedural Steps

Treatment begins by taking the daily dose in divided portions, such as two or three times a day, during the initial phase. After the initial treatment period, the dose is reduced to the maintenance level, which is typically taken once or twice daily. This reduction ensures that the minimum effective dose is maintained for long-term use. Treatment duration often extends for several months or is ongoing for conditions requiring sustained therapy.

If a dose is missed, standard practice involves skipping the missed dose and returning to the regular schedule at the next designated time; a double dose should not be taken to make up for the missed one.

Recent Clinical Evidence

Mesterolone: Recent Clinical Evidence

Research has investigated the use of Mesterolone in treating conditions associated with androgen deficiency, such as male hypogonadism and certain types of male infertility. The available evidence primarily consists of older clinical trials, though recent reviews and studies continue to examine its role in therapeutic contexts. The drug is categorized as an oral androgen.

One key area of research has examined the drug's influence on sperm quality and concentration in men experiencing idiopathic infertility. These studies evaluated Mesterolone's potential to modify certain parameters, particularly when baseline testosterone levels were near the lower end of the reference range.

Evaluation of Androgen Replacement and Effects

Clinical trials have historically reported findings regarding Mesterolone's ability to maintain secondary male characteristics and address symptoms of hypogonadism. Research has typically focused on the following outcomes:

  • Endpoint 1: Testosterone Levels: Studies assessed how Mesterolone administration influenced circulating testosterone and free testosterone levels, though results were observed to vary depending on the patient's existing endogenous production.
  • Endpoint 2: Efficacy in Infertility: The effect on sperm motility and density was evaluated, with some trials reporting changes compared to control groups or baseline measurements.

Specific Populations and Safety Concerns

Clinical data has also been used to evaluate Mesterolone's profile across specific populations. Due to its classification as an androgen, research has examined its potential metabolic effects.

Drug Interactions and Safety Evaluation

Studies investigated the drug's profile, including its oral bioavailability and its potential impact on liver function. The drug was generally evaluated in populations without pre-existing severe hepatic dysfunction. Research has explored outcomes across a range of studied dosages and treatment durations.

Frequently Asked Questions (FAQ)

Common questions about Mesterolone (FAQ)

Q: What is the half-life of Mesterolone?

According to official pharmacokinetic data, Mesterolone is rapidly absorbed after being taken orally. The drug typically reaches maximum serum levels in about two hours. After this peak, the amount of medicine in the body decreases, with a reported terminal half-life of 12 to 13 hours.

Q: How long does Mesterolone treatment typically last?

The official product information does not specify a maximum duration for Mesterolone treatment. Therapy may extend over several months or be ongoing, depending on the specific condition being addressed. This decision is made by a healthcare professional.

Q: Is Mesterolone safe to use long-term?

Due to its classification as an androgen, the official safety information indicates that precautions are necessary for long-term use. This includes recommendations for regular examinations of the prostate, especially for older male patients. These regular check-ups are specified to help monitor for potential risks associated with sustained androgen exposure.

Q: What is the correct way to dispose of expired Mesterolone tablets?

If Mesterolone is unused or expired, official guidance advises consulting a pharmacist for disposal instructions. The medicine should not be thrown into household trash or flushed down a toilet or drain. Proper disposal procedures are specified to help maintain safety and environmental protection.

Q: Is Mesterolone a controlled substance?

Yes, Mesterolone is classified as an Anabolic Androgenic Steroid (AAS). It is generally regulated as a controlled substance due to this classification, such as a Schedule III controlled substance in the United States.

Q: What is the difference between Mesterolone and Testosterone?

Mesterolone is a synthetic androgen derived from the natural hormone dihydrotestosterone (DHT), making it chemically distinct from testosterone itself. A key difference highlighted in the regulatory literature is that Mesterolone is non-aromatizable. This means it cannot be converted into estrogen within the body, which gives it a unique pharmacological profile compared to traditional testosterone.

How should Mesterolone be stored and disposed of?

How to Store and Dispose of Mesterolone?

The official storage guidelines for Mesterolone tablets are designed to maintain product stability and ensure household safety, based on government regulatory documentation.

Storage Conditions

Requirement Official Instruction
Temperature Store below 30 C (do not store above 30 C).
Protection Keep in a cool, dry place, protected from heat and dampness.
Packaging Must remain in the original packaging/blister until the time of use.
Safety Keep out of the sight and reach of children at all times.

Disposal Rules

To dispose of unused or expired Mesterolone, patients must consult a pharmacist for instructions. The medicine should not be thrown into household trash or flushed down the toilet or drain, even though the product is not classified as a special hazardous waste by regulatory documents. Return unused medicine to a pharmacist for safe, proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Mesterolone found in:

A-Z Index: